Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (100.0%)

Trials by Status

completed267%
recruiting133%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_1

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

NCT01799538
completedphase_1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

NCT02858310
completed

Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)

NCT02154880

Clinical Trials (3)

Showing 3 of 3 trials
NCT01799538Phase 1

Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis

Recruiting
NCT02858310Phase 1

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

Completed
NCT02154880

Translation Evaluation of Aging, Inflammation and HIV in Lung Function (TEAL)

Completed

All 3 trials loaded

Drug Details

Intervention Type
PROCEDURE
Total Trials
3